Checkpoint Therapeutics, Inc. (CKPT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful ...

Fintel reports that on January 13, 2025, D. Boral Capital initiated coverage of Checkpoint Therapeutics (NasdaqCM:CKPT) with a Buy recommendation. As of December 23, 2024, the average one-year price ...

Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report) is expected to announce its earnings results before the market opens on Friday, March 28th. Analysts expect the company to announce earnings of ...

Lake Street analyst Thomas Flaten reiterated a Buy rating on Checkpoint Therapeutics (CKPT – Research Report) today. The company’s shares closed yesterday at $2.05. Flaten covers the Healthcare sector ...

Officially completing its acquisition of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT), Sun Pharmaceutical Industries Ltd. has expanded its immuno-oncology footprint. The deal, announced earlier this ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) to Sun Pharmaceutical Industries Limited for ...